Free Trial
→ Your Bank Account Is No Longer Safe (From Priority Gold) (Ad)tc pixel

Genmab A/S (OTCMKTS:GNMSF) Shares Cross Above Fifty Day Moving Average - Time to Sell?

Written by MarketBeat
October 22, 2025
Genmab A/S logo with Medical background

Key Points

  • Genmab A/S shares have crossed above their 50-day moving average of $281.01, reaching a high of $303.50 before last trading at $289.99.
  • The company reported earnings per share (EPS) of $5.42 for the last quarter, exceeding the consensus estimate of $3.99, despite revenue falling short of expectations at $925 million.
  • Genmab has a market cap of $19.16 billion and maintains a net margin of 37.53% along with a return on equity of 21.03%.
  • Five stocks we like better than Genmab A/S.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $281.01 and traded as high as $303.50. Genmab A/S shares last traded at $289.99, with a volume of 581 shares.

Genmab A/S Price Performance

The company's fifty day moving average is $281.01 and its 200-day moving average is $232.99. The stock has a market cap of $19.16 billion, a PE ratio of 14.56 and a beta of 0.95.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to analysts' expectations of $949.06 million.

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover
Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.